No information is available on the clinical use of pazopanib during breastfeeding. Because pazopanib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 31 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during pazopanib therapy and for 2 weeks after the final dose.
关于帕唑帕尼在母乳喂养期间的临床应用尚无可用信息。由于帕唑帕尼与血浆蛋白的结合率超过99%，其在乳汁中的含量可能较低。然而，其半衰期约为31小时，可能会在婴儿体内蓄积。制造商建议在帕唑帕尼治疗期间及最后一剂后2周内停止母乳喂养。
